Search PubMed⌕ Search

Biomedical subjects

J Gueris

Publications and source records attributed to J Gueris.

At least 73 records · Page 4Linked to original sources
PubMed1977

[Effect of cortisone on calcium metabolism. Attempt at correction by 5,6 trans 25-hydroxycholecalciferol, 25-hydroxycholecalciferol and vitamin D2].

14 patients receiving small doses of predisolone and 7 high doses were divided at random into three groups. Each group received for four weeks, 100 microgram of vitamin D2 or 25 hydroxyvitamin D3 or 5,6 trans-25 hydroxyvitamin D3. The 25 hydroxy and 5,6 trans-25 hydroxyvitamine D3 were able to increase intestinal calcium absorption. 25 Hydroxyvitamin D3 had an osteolytic action, increasing urine calcium and hydroxyproline and, once, in a patient slight hypercalcemia was observed. By constrast, 5,6 trans-25 hydroxyvitamin D3 decreased PTH and caused a significant decrease in urine hydroxyproline.

Calcium↗
PubMed1977

[Radioimmunologic determination of plasma parathormone in hypercalcemia caused by cancer with osseous metastases].

The plasma parathormone was measured by radioimmunological determination in 23 cases of cancer with bone metastases, 8 of mammary origin. In 11 cases the plasma parathormone (iPTH) was less than 4 ng/ml (lower normal limit), as might be expected in view of the hypercalcemia. In 12 cases the iPTH was higher than 4 ng/ml, in 8 of these higher than 8 ng/ml (upper normal limit). These results are suggestive of the role of a substance analogous to parathormone in the genesis of the hypercalcaemia and peritumoral bone resorption of bone metastases of solid tumors.

Adult↗
PubMed1977

[Alpha-fetoproteins in maternal serum. Radioimmunologic determination in current obstetrical practice. Analysis of 669 determinations].

The analysis of 669 levels of maternal serum alpha-fetoproteins carried out using a radio-immunological technique with double antibodies has enabled a diagram of normal values to be established on the one hand has shown up certain modifications of levels when different pathological conditions arise in pregnancy on the other hand. Raised levels were found in: intra-uterine fetal death. In some cases the rise preceded death, in twin pregnancies. Low levels were found in: severe pre-eclamptic pregnancies, in low intra-uterine fetal growth after the 32nd week, in threatened premature labour. Finally, the levels of AFP in the maternal serum were found to be normal in two cases where there were neural tube malformations. The existence of variations in the levels of AFP in maternal serum in a variety of pathological features suggests that these levels could be used as a new parameter in the biochemical monitoring of the fetus.

Abortion, Spontaneous↗
PubMed1976

[Indications for arteriography and determination of parathyroid hormone in staged venous samplings in primary hyperparathyroidism].

The information provided by parathyroid arterigraphy and staged venous sampling with parathormone estimation is essentially related to localisation and is of little diagnostic value. It is not justifiable on a routine basis before all operations. These techniques are particularly useful in patients with practically definite hyperparathyroidism and who have already undergone a negative exploratory operation or surgery with insufficient excision.

Angiography↗
PubMed1976

1 alpha hydroxycholecalciferol and 25 hydroxycholecalciferol in renal bone disease.

Four microgrammes of 1-alpha-hydroxycholecalciferol (1-alpha-OH D3) or 200 mug of 25-hydroxycholecalciferol (25-OH D3) were given orally every other day respectively to 10 uraemic patients (8 on chronic haemodialysis) for 1-12 weeks and to 3 patients on chronic haemodialysis for 4-8 weeks. A transilial bone biopsy and serial evaluation of serum immunoreactive PTH (iPTH) calcium phosphate and alkaline phosphatase were performed before and at the end of therapy. Both 1-alpha-OH D3 and 25-OH D3 (the latter at a 50 times higher dose) were able to depress hyperparathyroidism in two-thirds of the cases and to consistently improve the mineralisation defect. In no case did iPTH or the bone histomorphometric parameters return to normal, so that long term evaluation of these two drugs is warranted.

Absorption↗
PubMed1975

[Current data on growth hormone].

The present concept of growth hormone is not that of an isolated hormone. Growth hormone is closely related to all other parts of system. Chemically, it belongs of to a family of 3 hormones, with prolactin and human placental lactogen. This chemical relationship produces some similar effects. Physiologically, it belongs to a series of hormonal secretions of which the elements are gradually recognized. Above, it is under the control of a releasing factor, still not identified : somatostatin which is an inhibiting factor, tetradecapeptide recently isolated ; below, the majority of the totality of its actions are developped through another hormone, or group of hormones : somatomedine. Present work on this endocrine system suggests new therapeutic prospects.

Animals↗
PubMed1975

[Heterogeneity of human plasma parathormone].

The heterogeneity in the plasma of peptide hormones has been known for some time. The demonstration of various fragments of circulating parathormone was undertaken using two antisera, which permitted the authors to study: -- the plasma half-life of parathormone; -- the variations in parathormone levels during dynamic tests; -- the limits between normal and pathological levels. It was thus demonstrated that the antisera recognised, in one case, the terminal carboxyl fragment, in the other case, the terminal amino fragment.

Antigen-Antibody Reactions↗